Koers Indiva Ltd Toronto S.E.
Aandelen
RMG
CA75088B2012
Farmaceutische producten
Omzet 2022 | 34,4 mln. 25,14 mln. 23,09 mln. | Omzet 2023 | 37,57 mln. 27,46 mln. 25,22 mln. | Marktkapitalisatie | 17,69 mln. 12,93 mln. 11,87 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -10 mln. -7,31 mln. -6,71 mln. | Nettowinst (verlies) 2023 | -4 mln. -2,92 mln. -2,68 mln. | EV/omzet 2022 | 1,01 x |
Nettoschuld 2022 | 19,22 mln. 14,05 mln. 12,9 mln. | Nettoschuld 2023 | 19,75 mln. 14,43 mln. 13,25 mln. | EV/omzet 2023 | 1 x |
K/w-verhouding 2022 |
-1,3
x | K/w-verhouding 2023 |
-3,26
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 65,43% |
Recentste transcriptie over Indiva Ltd
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Carmine Marotta
FOU | Founder | - | 13-09-79 |
Director of Finance/CFO | - | 13-12-17 | |
Chief Operating Officer | - | 01-05-19 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Rachel Goldman
BRD | Director/Board Member | 52 | 16-12-21 |
James Yersh
BRD | Director/Board Member | - | 13-12-17 |
Hugh Sutherland
BRD | Director/Board Member | - | 13-12-17 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+9,94% | 4,99 mld. | |
-32,21% | 3,61 mld. | |
-1,43% | 3,1 mld. | |
-25,09% | 2,64 mld. | |
-11,46% | 2,32 mld. | |
+36,65% | 1,85 mld. | |
+37,15% | 1,43 mld. | |
-16,01% | 1,39 mld. | |
+40,95% | 1,37 mld. |